SOUTH SAN FRANCISCO, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that management will discuss the amendment to the GlaxoSmithKline plc (NYSE: GSK; LSE) collaboration at 5:00 a.m. PST on Tuesday, January 11, 2005.

The discussion will be webcast and may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com/index.asp?secPage=events . An archive of this webcast will be available until 12:00 a.m. EST on January 25, 2005. Access numbers for this replay are: 1-877-519-4471 (domestic) and 1-973-341-3080 (international); Conference ID number is: 5588847.

About Exelixis

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics across various disease areas. The company is leveraging its fully integrated gene-to- drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a Phase 3 clinical trial has been initiated in patients with bile duct tumors; XL784, initially an anticancer compound, which completed a Phase 1 clinical trial and is being developed as a treatment for renal disease; XL647 and XL999, currently in Phase 1 clinical trials; XL880, for which an IND application has been filed; XL820, XL844 and XL184, potential IND candidates for the treatment of cancer; and multiple compounds in preclinical development for diseases including cancer, lipid disorders, hyperlipidemia and congestive heart failure. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb Company. The company has established agricultural research collaborations with Bayer CropScience and Dow AgroSciences. For more information, please visit the company's web site at www.exelixis.com.

SOURCE  Exelixis, Inc.
    -0-                             01/10/2005
    /CONTACT:  Charles Butler, Associate Director, Corporate Communications,
of Exelixis, Inc., +1-650-837-7277, or cbutler@exelixis.com/
    /Web site:  http://www.exelixis.com /
    (EXEL GSK)

CO:  Exelixis, Inc.; GlaxoSmithKline plc
ST:  California
IN:  MTC HEA BIO
SU:  CCA

MP-MC
-- SFM121 --
3363 01/10/2005 18:30 EST http://www.prnewswire.com